Skip to content

Study · In vitro (cells) · 2015

5 results

Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists.

Giacomini E, Severa M, Cruciani M, Etna MP, Rizzo F, Pardini M, Scagnolari C, Garaci E, Coccia EM

Expert opinion on biological therapy22 Jun 2015Cited by 19 (Europe PMC)

PMID26096650 (opens in a new tab)DOI10.1517/14712598.2015.1019460 (opens in a new tab)PepBankPUB-26096650
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human dendritic cells treated with viral TLR3 and TLR7/8 agonists, thymosin alpha‑1 enhanced HLA-I and II surface expression.

    In plain wordsIn cells, thymosin alpha‑1 increased immune-marker expression on dendritic cells exposed to viral signals.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHLA-I and II surface expression with viral TLR agonists
    Study

    humann: not reported in source

    Human primary monocyte-derived dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, Tα1 enhanced human leukocyte antigen (HLA)-I and II surface expression and secretion of IL-6, TNF-α and IL-8 when DCs were treated with viral TLR3 and TLR7/8 agonists.
    1 context sentence
    Summary · context
    The objective of this study was to determine whether Tα1 would address in vitro the response of human primary monocyte-derived DC, crucial regulators of vaccine-induced immunity, upon exposure to different toll-like receptor (TLR) agonists or infection with viruses or bacteria.
  2. 02LabIn vitro (cells)Efficacy outcome

    In human dendritic cells treated with viral TLR3 and TLR7/8 agonists, thymosin alpha‑1 enhanced secretion of IL-6, TNF-α and IL-8.

    In plain wordsIn cells, thymosin alpha‑1 increased inflammatory signals from dendritic cells exposed to viral signals.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-6, TNF-α and IL-8 secretion with viral TLR agonists
    Study

    humann: not reported in source

    Human primary monocyte-derived dendritic cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, Tα1 enhanced human leukocyte antigen (HLA)-I and II surface expression and secretion of IL-6, TNF-α and IL-8 when DCs were treated with viral TLR3 and TLR7/8 agonists.
    1 context sentence
    Summary · context
    The objective of this study was to determine whether Tα1 would address in vitro the response of human primary monocyte-derived DC, crucial regulators of vaccine-induced immunity, upon exposure to different toll-like receptor (TLR) agonists or infection with viruses or bacteria.
  3. 03LabIn vitro (cells)Efficacy outcome

    In pandemic H1N1 influenza A-infected human dendritic cells, thymosin alpha‑1 raised the expression of maturation markers.

    In plain wordsIn cells infected with flu virus, thymosin alpha‑1 increased markers of dendritic cell maturation.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMaturation markers in H1N1-infected dendritic cells
    Study

    humann: not reported in source

    Human primary monocyte-derived dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, in pandemic H1N1 influenza A-infected DCs, Tα1 raised the expression of maturation markers and type I and III Interferon (IFN).
    1 context sentence
    Summary · context
    The objective of this study was to determine whether Tα1 would address in vitro the response of human primary monocyte-derived DC, crucial regulators of vaccine-induced immunity, upon exposure to different toll-like receptor (TLR) agonists or infection with viruses or bacteria.
  4. 04LabIn vitro (cells)Efficacy outcome

    In pandemic H1N1 influenza A-infected human dendritic cells, thymosin alpha‑1 raised the expression of type I and III interferon.

    In plain wordsIn cells infected with flu virus, thymosin alpha‑1 increased interferon, an antiviral signal.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseType I and III interferon in H1N1-infected dendritic cells
    Study

    humann: not reported in source

    Human primary monocyte-derived dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, in pandemic H1N1 influenza A-infected DCs, Tα1 raised the expression of maturation markers and type I and III Interferon (IFN).
    1 context sentence
    Summary · context
    The objective of this study was to determine whether Tα1 would address in vitro the response of human primary monocyte-derived DC, crucial regulators of vaccine-induced immunity, upon exposure to different toll-like receptor (TLR) agonists or infection with viruses or bacteria.
  5. 05LabIn vitro (cells)Efficacy outcome

    In human dendritic cells stimulated with bacterial TLR2 and 4 agonists or infected with Bacillus Calmette-Guerin, thymosin alpha‑1 drastically lowered the analyzed cellular parameters.

    In plain wordsIn cells exposed to bacterial signals, thymosin alpha‑1 strongly lowered dendritic cell responses.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCellular parameters with bacterial TLR2/4 stimulation or BCG infection
    Study

    humann: not reported in source

    Human primary monocyte-derived dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, following bacterial TLR2 and 4 stimulation, as well as upon Bacillus Calmette-Guerin infection, the presence of Tα1 in DC cultures drastically lowered the analyzed cellular parameters.
    1 context sentence
    Summary · context
    The objective of this study was to determine whether Tα1 would address in vitro the response of human primary monocyte-derived DC, crucial regulators of vaccine-induced immunity, upon exposure to different toll-like receptor (TLR) agonists or infection with viruses or bacteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT05790447

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow Universityn = 60est. 1 Apr 2023 to est. Dec 2025

Advanced Solid Tumor · Refractory Tumor

Trial pageClinicalTrials.govUpdated 30 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.